Yahoo
BSE - Delayed Quote INR

Laurus Labs Limited (LAURUSLABS.BO)

2,392.00 +147.00 (+6.55%)
At close: October 30 at 3:58:08 PM GMT+5:30
Dividend
LAURUSLABS.BO announced a cash dividend of INR 1.00 with an ex-date of Nov. 6, 2026
Chart Range Bar
Loading chart for LAURUSLABS.BO
  • Previous Close 2,245.00
  • Open 2,245.00
  • Bid 2,392.00 x --
  • Ask --
  • Day's Range 2,207.10 - 2,392.00
  • 52 Week Range 913.35 - 2,392.00
  • Volume 606,077
  • Avg. Volume 87,979
  • Market Cap (intraday) 1.292T
  • Beta (5Y Monthly) 0.34
  • PE Ratio (TTM) 96.53
  • EPS (TTM) 24.78
  • Earnings Date (est.) Jan 22, 2027
  • Forward Dividend & Yield 2.00 (0.08%)
  • Ex-Dividend Date Nov 6, 2026
  • 1y Target Est 1,969.14

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company offers non-human ingredients; rare disease therapeutics; and finished dosages. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

www.lauruslabs.com

7,059

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

LAURUSLABS.BO
116.06%
S&P BSE SENSEX (^BSESN)
12.63%

1-Year Return

LAURUSLABS.BO
147.05%
S&P BSE SENSEX (^BSESN)
11.78%

3-Year Return

LAURUSLABS.BO
565.15%
S&P BSE SENSEX (^BSESN)
16.14%

5-Year Return

LAURUSLABS.BO
370.92%
S&P BSE SENSEX (^BSESN)
25.55%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY27
Revenue 22.06B
Earnings 4.41B
Profit Margin 20.01%

Q3

FY26

Q4

FY26

Q1

FY27

Q2

FY27

0
5B
10B
15B
20B
16.0%
18.0%
20.0%

Analyst Insights

View More

Analyst Price Targets

900.00 Low
1,969.14 Average
2,392.00 Current
2,830.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.13%

  • Return on Assets (ttm)

    11.28%

  • Return on Equity (ttm)

    23.97%

  • Revenue (ttm)

    78.23B

  • Net Income Avi to Common (ttm)

    13.4B

  • Diluted EPS (ttm)

    24.78

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    287.4M

  • Total Debt/Equity (mrq)

    42.47%

  • Levered Free Cash Flow (ttm)

    -4.31B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: